Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case Series
Natalia Rotter(Krankenhaus der Elisabethinen), Thomas Melchardt(Paracelsus Medical University), Michael Leisch(Paracelsus Medical University), Richard Greil(Paracelsus Medical University), Ferdinand Haslbauer(Tirol Kliniken), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Beatrice Casadei(Istituto di Ematologia di Bologna), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Felix Keil(Hanusch Hospital), Holger Rumpold(Johannes Kepler University of Linz), Alexander Egle(Paracelsus Medical University), Agnes List(Hanusch Hospital), Olga Saini(Johannes Kepler University of Linz), Markus Raderer(Medical University of Vienna), Teresa Magnes(Paracelsus Medical University), Georg Hess(Johannes Gutenberg University Mainz), Emine Kaynak(Krankenhaus der Elisabethinen)
Cited by 0
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523